A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

NCT06759649 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm
Cancer, Malignant Tumors

Interventions

DRUG: COM503
DRUG: Zimberelimab

Sponsor

Compugen Ltd

Collaborators

[object Object]